Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ: VRTX )

495.42 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
58 59 Next >
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Via Benzinga
3 Breakout Biotech Stocks on Track to Double by 2032
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify. 
Via InvestorPlace
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
The latest bull market has plenty of intriguing buying opportunities. 
Via The Motley Fool
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
Growth stocks with wide moats and strong financials can compound investor returns with time. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These healthcare stocks have clear paths to growth over the next few years. 
Via The Motley Fool
2 Healthcare Stocks That Are Screaming Buys in June
These top healthcare stocks are no-brainer buys in 2024 and beyond. 
Via The Motley Fool
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
NASDAQ:VRTX is not too expensive for the growth it is showing. 
Via Chartmill
13 Analysts Have This To Say About Vertex Pharmaceuticals
Via Benzinga
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Invest in the top biotech stocks to buy, as the sector pivots from pandemic-driven vaccine sales to solutions for chronic conditions. 
Via InvestorPlace
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
The biotech's shares have traded sideways for over a year, but better days could be on the near-term horizon. 
Via The Motley Fool
3 Biotech Stocks That Could Make Your Grandchildren Rich
These biotech stocks are poised to generate significant returns to investors due to their high growth potential. 
Via InvestorPlace
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
It looks like Vertex's experimental new therapy could become a functional cure for lots of people with diabetes. 
Via The Motley Fool
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Why NASDAQ:VRTX Stands Out as a Quality Stock. 
Via Chartmill
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Lilly is a good pick...but this one is better. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Evergreen business models make it easier to hold for the long run. 
Via The Motley Fool
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having... 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks. 
Via The Motley Fool
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Healthcare Stocks to Buy Hand Over Fist in June
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.